What next for acquisition-hungry Valeant?
This article was originally published in Scrip
Valeant Pharmaceuticals' CEO J Michael Pearson was in Asia when the news broke at the start of this week that Valeant had lost out to Actavis in its bid for Allergan. As a result, "We haven't had time to do a post mortem," according to Laurie Little, Valeant's VP of investor relations, speaking at the Jefferies Global Healthcare Conference on 19 November. However, there's "no urgency" to get another big deal going. "We need a few days' rest," she said. "It would be good to string a few quiet quarters together."